Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 42, 2016, Pages 11919-11924

  Subudhi, Sumit K ^a   Aparicio, Ana ^a   Gao, Jianjun ^a   Zurita, Amado J ^a   Araujo, John C ^a   Logothetis, Christopher J ^a   Tahir, Salahaldin A ^a   Korivi, Brinda R ^a   Slack, Rebecca S ^a   Vence, Luis ^a   Emerson, Ryan O ^b   Yusko, Erik ^b   Vignali, Marissa ^b   Robins, Harlan S ^b,c   Sun, Jingjing ^a   Allison, James P ^a   Sharma, Padmanee ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ADAPTIVE BIOTECHNOLOGIES   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

CD8; Ipilimumab; Prostate cancer; T cells; Toxicities

Indexed keywords

DEGARELIX; IPILIMUMAB; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; T LYMPHOCYTE RECEPTOR BETA CHAIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CD8+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL ARTICLE; COHORT ANALYSIS; COLITIS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FOLLOW UP; HUMAN; HUMAN CELL; HYPERTRANSAMINASEMIA; HYPOPHYSITIS; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATECTOMY; RETROSPECTIVE STUDY; SYSTEMIC CIRCULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADVERSE DRUG REACTION; CLONAL EVOLUTION; COMPLICATION; DISEASE PREDISPOSITION; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE TUMOR; SEVERITY OF ILLNESS INDEX; T LYMPHOCYTE SUBPOPULATION;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS, PHASE II AS TOPIC; CLONAL EVOLUTION; DISEASE SUSCEPTIBILITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IPILIMUMAB; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 84991691484     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1611421113     Document Type: Article

References (30)

1. Hodi FS, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711-723.
2. Robert C, et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517-2526.
3. Robert C, et al.; KEYNOTE-006 investigators (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372(26):2521-2532.
4. Weber JS, et al. (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375-384.
5. Borghaei H, et al. (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627-1639.
6. Brahmer J, et al. (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123-135.
7. Motzer RJ, et al.; CheckMate 025 Investigators (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803-1813.
8. Small EJ, et al. (2007) A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13(6):1810-1815.
9. Beer T, et al. (2008) Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 26(15S):5004.
10. Gerritsen W, et al. (2008) Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC). J Clin Oncol 26(15S):5146.
11. Lynch TJ, et al. (2012) Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30(17):2046-2054.
12. Kwon ED, et al.; CA184-043 Investigators (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15(7):700-712.
13. Gao J, et al. (2015) Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene 34(43):5411-5417.
14. Larkin J, et al. (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23-34.
15. Tumeh PC, et al. (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568-571.
16. Scher HI, et al.; Prostate Cancer Clinical Trials Working Group (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7):1148-1159.
17. Liakou CI, et al. (2008) CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 105(39):14987-14992.
18. Carthon BC, et al. (2010) Preoperative CTLA-4 blockade: Tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16(10):2861-2871.
19. Ng Tang D, et al. (2013) Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 1(4):229-234.
20. Cha E, et al. (2014) Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med 6(238):238ra70.
21. Santegoets SJ, et al. (2013) T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother 62(2):245-256.
22. Kwek SS, et al. (2015) Pre-existing levels of CD4 T cells expressing PD-1 are related to overall survival in prostate cancer patients treated with ipilimumab. Cancer Immunol Res 3(9):1008-1016.
23. Ansell SM, et al. (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372(4):311-319.
24. Kyi C, Hellmann MD, Wolchok JD, Chapman PB, Postow MA (2014) Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer 2:19.
25. Arriola E, et al. (2015) Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control. OncoImmunology 4(10):e1040218.
26. Fong L, et al. (2009) Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 69(2):609-615.
27. Wolchok JD, et al. (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11(2):155-164.
28. Robins HS, et al. (2009) Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 114(19):4099-4107.
29. Carlson CS, et al. (2013) Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun 4:2680.
30. DeWitt WS, et al. (2015) Dynamics of the cytotoxic T cell response to a model of acute viral infection. J Virol 89(8):4517-4526.